	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	524	661	739	825	1,080	2,065	2,185	2,095	1,915	2,052	1,945	2,707	3,999	4,430	4,078
Cost of Operating Revenue	255	321	330	353	404	765	594	555	599	727	819	913	1,052	1,034	897
Gross Profit	268	340	409	473	676	1,300	1,591	1,540	1,316	1,325	1,126	1,794	2,946	3,396	3,181
Gross Margin	51.3	51.5	55.3	57.3	62.6	63.0	72.8	73.5	68.7	64.6	57.9	66.3	73.7	76.7	78.0
Total Operating Expenses	430	533	590	659	861	1,433	1,323	1,379	1,432	1,563	1,824	1,928	2,431	2,419	2,848
Operating Profit	94	128	149	166	219	632	862	716	483	489	121	779	1,567	2,011	1,230
Operating Margin	17.9	19.3	20.2	20.1	20.3	30.6	39.5	34.2	25.2	23.8	6.2	28.8	39.2	45.4	30.2
Financing Income/(Expense) - Net	-15	-18	-22	-23	-22	-6	13	93	63	47	32	58	92	186	-37
Profit before Taxes	80	102	129	134	202	624	887	825	569	580	202	862	1,674	2,291	1,491
Income Taxes	21	36	31	4	48	140	192	182	111	137	32	147	285	408	119
Profit after Tax	60	72	103	135	157	486	696	644	461	441	170	715	1,388	1,885	1,419
PAT Margin	11.4	10.9	13.9	16.3	14.5	23.5	31.9	30.8	24.1	21.5	8.7	26.4	34.7	42.6	34.8
EPS - Basic - ex Extraordinary Items	4.11	4.60	6.43	8.13	9.09	27.89	39.26	34.98	25.33	24.20	9.32	39.18	77.34	105.27	79.20
EPS - Diluted - ex Extraordinary Items	4.11	4.58	6.43	8.13	9.06	27.87	39.13	34.87	25.26	24.16	9.32	39.18	77.34	105.27	79.20
EBIT	94	128	149	166	219	632	862	716	483	489	121	779	1,567	2,011	1,230
EBITDA	110	150	179	213	270	686	928	797	583	606	264	943	1,754	2,196	1,437
EBITDA Margin	20.9	22.7	24.3	25.9	25.0	33.2	42.5	38.1	30.4	29.5	13.5	34.8	43.9	49.6	35.2

Balance Sheet

Abridged

Understanding Balance Sheet

Natco Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	293	330	368	488	837	1,087	2,131	2,347	2,326	2,337	2,497	3,000	4,024	5,270	5,052
Long-Term Investments	62	2	2	5	4	6	14	26	87	163	108	87	121	309	335
Property Plant & Equipment - Net	465	660	737	793	916	1,164	1,493	1,856	2,094	2,237	2,308	2,303	2,435	2,657	2,839
Total Non-Current Assets	612	750	828	894	985	1,230	1,584	1,956	2,262	2,455	2,612	2,657	2,883	3,361	6,021
Total Assets	905	1,080	1,196	1,382	1,822	2,318	3,715	4,303	4,588	4,792	5,109	5,657	6,906	8,631	11,074
Total Current Liabilities	259	345	312	414	493	627	592	729	685	526	710	683	973	944	1,681
Long Term Debt	134	138	95	97	-	-	-	-	1	1	8	1	5	5	104
Total Non-Current Liabilities	171	191	151	119	28	38	47	83	118	143	135	101	80	75	172
Total Liabilities	431	536	463	533	521	664	639	812	803	669	846	784	1,053	1,019	1,853
Total Shareholders' Equity	474	534	726	845	1,296	1,649	3,072	3,489	3,774	4,122	4,264	4,874	5,853	7,607	9,221
Minority Interest	1	11	7	5	5	4	4	2	11	2	-	-	-	5	-
Total Equity	475	544	733	850	1,301	1,653	3,076	3,491	3,785	4,123	4,264	4,874	5,853	7,612	9,221
Total Liabilities & Equity	905	1,080	1,196	1,382	1,822	2,318	3,715	4,303	4,588	4,792	5,109	5,657	6,906	8,631	11,074

Cash Flow

Abridged

Understanding Cash Flow Statement

Natco Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	67	99	128	152	228	591	753	694	580	566	311	821	1,562	2,029	1,372
Working Capital - Increase/(Decrease)	-28	-67	-16	-86	-141	-253	-295	9	-98	-213	-231	63	-309	-200	646
Net CF from Operating Activities	39	32	112	66	88	338	458	703	483	353	80	884	1,252	1,829	2,017
Capital Expenditures - Net	129	112	111	118	138	280	407	444	337	207	189	175	357	397	390
Net CF from Investing Activities	-129	-110	-111	-118	-177	-307	-1,126	-665	-254	-170	-55	-526	-1,092	-1,564	-2,367
Dividends Paid - Cash - Total	11	14	19	20	26	141	181	111	154	114	82	100	171	108	90
Stock - Issuance/(Retirement) - Net	68	0	109	-	334	-	896	-135	-54	0	-	-7	-254	7	-
Debt - LT & ST - Issuance/(Retirement) - Total	33	70	-91	71	-129	109	-48	213	-81	-50	136	-241	196	-89	424
Net Cash Flow from Financing Activities	91	58	-1	59	180	-32	667	-32	-229	-173	52	-349	-229	-190	333
Free Cash Flow to Equity	-56	-10	-90	19	-180	167	3	472	65	96	26	468	1,091	1,343	2,051
Free Operating CF net dividend	-100	-94	-19	-74	-96	-83	-148	130	-30	-15	-245	578	723	1,210	1,536
Free Operating CF	-90	-80	1	-54	-70	58	34	241	124	99	-163	678	894	1,318	1,626

Business Segment Analysis

FY End:

Mar 25

Natco Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Pharmaceuticals (98.6%)₹ 4,368.90 CrAgro Chemicals (1.4%)₹ 60.60 Cr

Assets

Pharmaceuticals (62.6%)₹ 5,399.40 CrUnallocated (34.3%)₹ 2,960.20 CrAgro Chemicals (3.1%)₹ 271.20 Cr

Regional Segment Analysis

FY End:

Mar 25

Natco Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

United States (71.1%)₹ 3,148.70 CrRest of the world (16.1%)₹ 713.90 CrIndia (12.8%)₹ 566.90 Cr

Historical Segment Analysis

Track how Natco Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31

Bulk Chemicals	15	30	86	89	41	27	32
Eliminations	0	0	0	0	0	0	0
Finished Dosage Formulations	22	50	54	28	53	59	41
Job Works	0	0	0	0	0	0	0
Other	0	15	12	25	7	6	32
Pharmacy	0	3	1	1	1	0	0
Unallocable	2	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Natco Pharma Ltd.?

The latest trailing twelve month revenue of Natco Pharma Ltd. is ₹ 4,078.30 Cr, reflecting a 1-year growth of -7.93% and a 3-year CAGR of 14.64%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Natco Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Natco Pharma Ltd. is ₹ 1,418.50 Cr, with a 3-year earnings CAGR of 26.44%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Natco Pharma Ltd.?

The trailing twelve month EBITDA of Natco Pharma Ltd. is approximately ₹ 1,229.90 Cr (based on an operating margin of 30.16%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Natco Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Natco Pharma Ltd. is 79.20. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Natco Pharma Ltd.?

The debt-to-equity ratio of Natco Pharma Ltd. stands at 0.08. The interest coverage ratio is 33.51x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Natco Pharma Ltd.?

The estimated book value per share of Natco Pharma Ltd. is 514.91 (derived from a P/B ratio of 1.88 and market price of ₹ 967.85), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Natco Pharma Ltd.?

The trailing twelve month operating cash flow of Natco Pharma Ltd. is ₹ 2,017.20 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Natco Pharma Ltd. report consolidated or standalone financials?

Natco Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.